Using a mechanistic pathway or agent to achieve something else than it was designed to do, leaves questions unanswered that will become clear only over time. Ali Pashazadeh, Treehill Partners CEO, is quoted commenting on long-term safety outlook for GLP-1 in Endpoints article:
https://endpts.com/novo-offers-detailed-look-at-semaglutides-cardiac-outcomes-in-phase-3-trial-as-it-tees-up-resubmission/
(subscription to Endpoints required)